Results 61 to 70 of about 3,014 (182)

Advances in FGF/FGFR Signaling: Implications for Disease and Therapy

MedComm, Volume 7, Issue 9, September 2026.
The FGF/FGFR signaling is indispensable for the maintenance of physiological homeostasis and governs multiple biological processes, including embryonic development, bone metabolism, angiogenesis, and neurogenesis, whereas aberrant hyperactivation of this pathway drives the progression of malignancies and autoimmune disorders, including inflammatory ...
Miaoyu Song, Xi Liu, Yang Xiao, Yongsheng Li, Huakan Zhao   +4 more
wiley   +1 more source

Leveraging Healthy Volunteers for Anticancer Drug Clinical Pharmacology Studies: A Review Article Featuring Futibatinib as an Example

Clinical and Translational Science, Volume 19, Issue 9, September 2026.
ABSTRACT Early clinical development of anticancer drugs traditionally focused on exploring candidate treatments in patients. For instance, due to their cytotoxic action, administration of chemotherapies to healthy volunteers (HVs) for evaluation of their pharmacokinetic profiles was not considered feasible nor ethical from a safety and tolerability ...
Aernout D. van Haarst, Sabina Paglialunga, Ziv Machnes, Ikuo Yamamiya, Nanae Hangai, Aram Oganesian   +5 more
wiley   +1 more source

Comparative Response of Canine and Human Osteosarcoma Tumour Cell Lines to Molecularly Targeted Anticancer Agents at Clinically Relevant Exposures With Analysis of Genomic Biomarkers

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 532-544, September 2026.
ABSTRACT Osteosarcoma (OSA) is a primary bone tumour occurring in children but is also prevalent in large breed dogs. Canine OSA (cOSA) has long been viewed as analogous to human OSA (hOSA) with cOSA serving as a surrogate for development of therapeutic approaches to treat the rarer human form.
Daniel L. Gustafson, Kala A. Early, Maritza A. Morales, Klaudia A. Poplawski, Sunetra Das, Dawn L. Duval   +5 more
wiley   +1 more source

Supplementary Data from Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

, 2019
Supplementary Table S1. Arithmetic Mean {plus minus} SD Plasma Erdafitinib Pharmacokinetic Parameters after the First Erdafitinib Administration (Cycle 1 Day 1) or at Steady-State (Cycle 2 Day 1) in Patients Assigned to the Continuous Daily Dosing or the
Alain Mita (6295982), Alexander Spira (11395472), Ramaswamy Govindan (60360), Martha Gonzalez (3638434), Mark Awad (6525626), Trilok Parekh (15018212), Italo Poggesi (2396347), Jeffrey Infante (3816376), Josep Tabernero (237681), Bob Zhong (15018209), Rastislav Bahleda (13011628), Ademi Santiago-Walker (15001046), Victor Moreno (748751), Hong Xie (133048), Emiliano Calvo (6271580), Andres Cervantes (8456292), Cinta Hierro (15018206), Antoine Italiano (725114), Nancy Chan (6727526)   +18 more
core   +1 more source

Identification of Novel Therapeutic Agent Candidates Through High Throughput Screening With Chemical Library Based on Molecular Subclassification in Canine Histiocytic Sarcoma Cell Lines

Veterinary and Comparative Oncology, Volume 24, Issue 3, Page 554-567, September 2026.
ABSTRACT Effective chemotherapy for canine histiocytic sarcoma (CHS) has yet to be established. In our previous study, CHS cell lines were subclassified into two groups based on their gene expression profiles: Group A and Group B. This study aimed to identify novel therapeutic agents that are effective against each CHS subgroup, and we performed high ...
Hiroki Sakuma, Hirotaka Tomiyasu, Mari Takamiya, Yuko Goto‐Koshino, Atsushi Tsukamoto, Makoto Bonkobara, Masaru Okuda   +6 more
wiley   +1 more source

Erdafitinib in Patients with High- and Intermediate-risk Non–muscle-invasive Bladder Cancer: Final Analysis of THOR-2 Study [PDF]

Background and objective: High-risk (HR) or intermediate-risk (IR) non–muscle-invasive bladder cancer (NMIBC) carries a high probability of recurrence and/or progression.
Shimizu, Nobuaki, Vasdev, Nikhil, Lotan, Yair, Procopio, Giuseppe, Lee, Eugene K, Maranchie, Jodi K, Baig, Mahadi, Pignot, Geraldine, Tran, Ben, Daneshmand, Siamak, Crow, Lauren, Naini, Vahid, Zhu, Wei, Triantos, Spyros, Deprince, Kris, Master, Viraj A., Zaucha, Renata, Catto, James W.F., Tubaro, Andrea, Galanternik, Fernando   +19 more
core   +1 more source

Grade 3 Hepatotoxicity following Fulvestrant, Palbociclib, and Erdafitinib Therapy in a Patient with ER-Positive/PR-Negative/HER2-Negative Metastatic Breast Cancer: A Case Report

Case Reports in Oncology, 2020
A 49-year-old woman with ER-positive/PR-negative/HER2-negative metastatic breast cancer experienced Grade 3 hepatotoxicity following initiation of a clinical trial of fulvestrant, palbociclib, and erdafitinib.
Alyssa Schlotman, Adam Stater, Kyle Schuler, Judd Heideman, Vandana Abramson   +4 more
doaj   +1 more source

Dual PI3K/AKT and CDK4/6 inhibition reveals selective sensitivity in an SHH medulloblastoma stem cell model

Molecular Oncology, Volume 20, Issue 7, Page 1800-1813, July 2026.
Targeted therapy was evaluated in SHH medulloblastoma using neuroepithelial stem cell (NES) and tumor‐derived NES‐like (tNES) models in 2D monolayers and 3D spheroids. PI3K, AKT, and CDK4/6 inhibitors had minimal effects in NES but markedly reduced viability and growth and induced apoptosis in tNES cells, revealing distinct therapeutic vulnerabilities.
Monika Lukoseviciute, Madeleine Birgersson, Paolo Ceriani, Margareta Wilhelm, Ourania N Kostopoulou   +4 more
wiley   +1 more source

Erdafitinib [PDF]

Reactions Weekly, 2020
openaire   +2 more sources

Data mining and safety analysis of FGFR tyrosine kinase inhibitors based on the FAERS database

Scientific Reports
Fibroblast growth factor receptor tyrosine kinase inhibitors (FGFR-TKIs), including erdafitinib, pemigatinib, and futibatinib, are a promising class of therapies for FGFR-driven cancers.
Ping Li, Liming Wu, Zhihui Song
doaj   +1 more source